News

Funxional Therapeutics has completed the first phase I study of FX125L, an orally available small molecule which belongs to Broad Spectrum Chemokine Inhibitors (BSCIs). FX125L, an Anti-Inflammatory Drug,

AlphaRx has reported positive preclinical results on GAI-122 injectable nano-emulsion in multiple models of acute hepatitis. GAI-122 reduced Aminotransferase (ALT) following IP administration in three different preclinical models

Novartis has received the approval for Rasilez (aliskiren), a high blood pressure medicine, for use in Japan. Rasilez directly inhibits renin, an enzyme that triggers a process leading

FDA has accepted for review, Eisai’ supplemental new drug application (sNDA) for an alternative five-day dosing regimen for Dacogen (decitabine for injection). It is intended to treat patients

GlaxoSmithKline announces the final analysis of the efficacy trial of a cervical cancer vaccine. The study, involving 18,644 women, confirmed GlaxoSmithKline’s Cervarix is effective at protecting against the

King Pharmaceuticals and Pain Therapeutics have announced that on July 2, 2009, King met with the FDA to discuss the Complete Response Letter regarding the New Drug Application

Celgene has filed a New Drug Application (NDA) with the Japanese Ministry of Health, Labour and Welfare (MHLW) for Revlimid (lenalidomide) in combination with dexamethasone for the treatment

Kineta and Airmid have announced an agreement in which a Kineta subsidiary has acquired exclusive commercial rights to a portfolio of novel therapeutic compounds from Airmid. The array

Galapagos has successfully identified a second pre-clinical candidate compound in its osteoarthritis alliance with GlaxoSmithKline (GSK). Galapagos also reached a milestone on another compound in the alliance. Together